A major public health announcement issued today at alternative websites across the worldwide web about a natural remedy for Chikungunya virus, a mosquito-borne infectious disease that plagues millions of people living in equatorial countries, is not being issued by major public health agencies. Instead, a groundbreaking study (see press release below) was privately funded by a small research team of dedicated researchers in Reno, Nevada.
In the aforementioned study, albeit a small pilot human clinical trial, 97% of study subjects experienced a profound and rapid clinical effect, not just a statistical improvement, that would be anticipated to make a demonstrable impact on public health globally.
While these
have been on, COVID-19 vaccines have been unequally distributed around the world. Rich countries signed agreements to buy up the bulk when vaccines were still being developed. Many players are involved in the development and distribution of COVID-19 vaccines countries and their governments; research institutions such as Oxford University; and pharmaceutical companies such as AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Pfizer, Moderna, Novavax and the Serum Institute of India. Global alliances have also been participating in the process, such as GAVI, which is a global alliance facilitating vaccine production and distribution, the Coalition for Epidemic Preparedness Innovations or CEPI, and COVAX, an alliance specifically to coordinate distribution of COVID-19 vaccines that is led by GAVI ad CEPI. The Gates Foundation helped set up both GAVI and CEPI, and had contributed to funding COVAX.
EU now open to vaccine waiver, after Biden U-turn
In total more than 100 countries back the temporarily waiver of intellectual property rights for Covid-19 vaccines (Photo: UNICEF Ethiopia)
Brussels, Today, 07:15
The European Union is ready to discuss the proposal, now supported by the United States, to temporarily waive intellectual property rights for Covid-19 vaccines - after opposing the move during seven months of negotiations at the international level. The EU is also ready to discuss any proposals that addresses the crisis in an effective and pragmatic manner, European Commission president Ursula von der Leyen said in a speech to the European University Institute in Florence on Thursday (6 May).
Provisión de materias primas, claves para la liberación de las patentes de vacunas - Mundo abc.com.py - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abc.com.py Daily Mail and Mail on Sunday newspapers.